New statement highlights nurses’ role in managing psychosocial health after stroke

An oral ver­sion of No­vo Nordisk’s semaglu­tide helped pa­tients tak­ing the high­est dose lose 15% of their body weight. It’s on par with No­vo’s We­govy,

Cor­bus Phar­ma­ceu­ti­cals re­port­ed en­cour­ag­ing ear­ly-stage re­sults for its Nectin-4 tar­get­ing ADC in var­i­ous types of can­cer, but a lack of re­sponse in cer­tain pa­tients caused